GENEART AG and Applied Biosystems Deutschland GmbH intend to conclude a domination agreement
Geneart AG / GENEART AG and Applied Biosystems Deutschland GmbH intend to conclude a domination agreement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Regensburg/Darmstadt, June 11, 2010 - GENEART AG and its majority shareholder,
Applied Biosystems Deutschland GmbH, intend to conclude a domination agreement
pursuant to Section 291 et seq. German Stock Corporation Act (Aktiengesetz) with
GENEART AG as the dominated entity and Applied Biosystems Deutschland GmbH as
the dominating entity. GENEART AG and Applied Biosystems Deutschland GmbH want
to execute such agreement before GENEART AG's annual general meeting scheduled
for August 19, 2010. The domination agreement shall be submitted for approval to
GENEART AG's general meeting in the context of the company's annual general
meeting scheduled for August 19, 2010.
For further inquiries, please contact:
Dr. Karoline Stürmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: +49-(0)941-942 76-417
Fax: +49-(0)941-942 76-711
ir@geneart.com
www.geneart.com
Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: +49-(0)89-8896906-10
Fax: +49-(0)89-8896906-66
info@better-orange.de
www.better-orange.de
Legal Information:
This document may contain estimates, prognoses and opinions about company plans
and objectives, products or services, future results, opinions about these
results or opinions leading up to these results. All these projections into the
future are subject to risk, uncertainty and unforeseeable change outside the
control of the GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG:
In 2000 GENEART entered the Gene Synthesis market and has since become the
global market leader. Today, the company is one of the leading specialists in
the Synthetic Biology field. Experts at GENEART provide key technologies for the
development and production of new therapeutics and vaccines. Customers also take
advantage of GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct bacteria,
which produce complex biopolymers or break down polymers, such as synthetics,
petroleum components, etc. GENEART's service portfolio ranges from the
optimization and production of synthetic genes according to DIN EN ISO
9001:2008, to the generation of gene variants or complex gene libraries and the
production of cell lines, to the development and production of DNA and protein
based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART
Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about
180 people. The company is listed on the German Stock Exchange since May 2006.
Since April 2010, the US-American Life Technologies Corporation, one of the
leading biotechnology companies worldwide with 2009 revenues of USD 3.3B and
about 9,000 employees, is majority shareholder of GENEART AG.
About Life Technologies Corporation:
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools
company dedicated to improving the human condition. Our systems, consumables and
services enable researchers to accelerate scientific exploration, driving to
discoveries and developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to advance
personalized medicine, regenerative science, molecular diagnostics, agricultural
and environmental research, and 21st century forensics. Life Technologies had
sales of USD 3.3B in 2009, employs approximately 9,000 people, has a presence in
approximately 160 countries, and possesses a rapidly growing intellectual
property estate of approximately 3,900 patents and exclusive licenses. Life
Technologies was created by the combination of Invitrogen Corporation and
Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and
research use only-labeled products. For more information on how we are making a
difference, please visit our website:http://www.lifetechnologies.com
.
[HUG#1423210]
--- End of Message ---
Geneart AG
Josef-Engert-Str.11 Regensburg Germany
ISIN: DE000A0JJ4L4;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
Press release (PDF): http://hugin.info/136633/R/1423210/372108.pdf
